WBB Securities Starts ContraFect Corp. (CFRX) at Speculative Buy
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
WBB Securities analyst Steve Brozak initiates coverage on ContraFect Corp. (NASDAQ: CFRX) with a Speculative Buy rating and a price target of $6.50.
The analyst commented, "Though the COVID-19 pandemic has received most attention during the past year, it is imperative that the medical R&D community continue to devote efforts to developing new treatments for AMR infections. We believe the CFRX research and development pipeline represents a crucial medical advancement that can reverse the growing threat of bacterial resistance to the currently available standard-of-care (SOC) antibiotics that key opinion leaders have said could force medicine to retreat to a pre-penicillin era. We are therefore initiating coverage of CFRX with a Speculative Buy rating and a 12-month price target of $6.50."
Shares of ContraFect Corp. closed at $4.48 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Stephens Starts First Solar (FSLR) at Overweight
- Melrose Industries PLC (MRO:LN) (MLSPF) PT Lowered to GBP1.85 at UBS
- UPDATE: Stephens Starts SolarEdge Technologies (SEDG) at Overweight
Create E-mail Alert Related CategoriesAnalyst Comments, New Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!